2 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Refractory Leukemia: new trials by email Literature Review of Refractory Leukemia trials Research Report on Refractory Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm CD123 targeted CAR-NK cells - Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1 / Phase 2 | Completed | Chongqing Precision Biotech Co., Ltd | 5 | 2024-03-28 | 2026-08-05 |
| Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children Carfilzomib, Cyclophosphamide, Etoposide - Relapsed Solid Tumors, Refractory Solid Tumors | Phase 1 | Completed | Stanford University | 4 | 2016-02-16 | 2025-10-15 |
Leukemia (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Leukemia, Myeloid, Acute (1) · Recurrence (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Disease Attributes (1) · Hematologic Neoplasms (1) · Histiocytic Disorders, Malignant (1) · Leukemia, Myeloid (1) · Lymphoma (1) · Neoplasms by Site (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Skin Diseases (1) · Skin Neoplasms (1) · Skin and Connective Tissue Diseases (1)
Cyclophosphamide (1) · Etoposide (1) · carfilzomib (1)
Chongqing Precision Biotech Co., Ltd (1) · Stanford University (1)
Canada (1) · China (1) · United States (1)
Jia Wei, M.D (1)